immunotherapeutic agent Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 1 (1)

Interventional (1)

Big Ten Cancer Research Consortium (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadstem cell transplant

I am/have/hadimmunohistochemistry

I am/have/hadlymphoma

I am/have/hadmalt

I am/have/hadcirrhosis

I am/have/hadindolent lymphoma

I am/have/hadcrohn's disease

I am/have/hadsymptomatic congestive heart failure

I am/have/hadhair thinning

I am/have/hadhepatitis c

I am/have/hadhashimoto syndrome

I am/have/hadpsychiatric disorder

I am/have/hadinterstitial lung disease

I am/have/hadcell transplantation

I am/have/hadangina

I am/have/hadmarginal zone lymphoma

I am/have/hadulcerative

I am/have/hadheart failure

I am/have/hadvasectomy

I am/have/hadautograft

added new label for I am/have/had

more

I am looking for

I am looking forcopanlisib

I am looking forcyp3a4 inhibitors

I am looking forattenuated vaccines

I am looking forprednisone

I am looking fornivolumab

I am looking forendocrine therapy

I am looking forcyp3a4 inducers

I am looking forimmunosuppressive agents

I am looking forpi3k inhibitor

I am looking forcorticosteroids

I am looking forhormone therapy

I am looking forhba1c

I am looking forrituximab

I am looking forhepatitis b surface antigen

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Recruiting

Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor Copanlisib Given in Combination With the Immunotherapeutic Agents Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Patients with relapsed or refractory follicular or marginal zone lymphoma who have received at least one prior line of therapy will receive Copanlisib IV: day 1, 8, 15 every 28 days Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only Rituximab IV: Cycle 1 days 1, 8, …

stem cell transplant

immunohistochemistry

lymphoma

malt

cirrhosis

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2024 All rights reserved.